Medium dose BI 3812465
Preclinical
Boehringer IngelheimMedium dose BI 3812465 is one of 27 therapeutic programs targeting Diabetic Macular Edema. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
180 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Beovu
NovartisPhase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Synalar
EEurofarma Laboratorios S.A.
Phase 3
Lucentis
NovartisPhase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Intravitreal Ranibizumab
RochePhase 3
Glucophage
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Medium dose BI 3812465. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company